Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction

European Respiratory Journal

Volumn 9, Issue 8, 1996, Pages 1689-1695

  Paggiaro, P L ^a,c   Giannini, D ^a   Di Franco, A ^a   Testi, R ^b  

^a UNIVERSITY OF PISA   (Italy)

^b GSK   (Italy)

^c CISANELLO HOSPITAL   (Italy)

Author keywords

Asthma treatment; Bronchodilator drugs; Salmeterol; Theophylline; agonists

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMOGLYCATE DISODIUM; KETOTIFEN; METHYLXANTHINE DERIVATIVE; NEDOCROMIL; SALMETEROL; STEROID; THEOPHYLLINE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; GASTRITIS; HEADACHE; HEART PALPITATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; TACHYCARDIA; THEOPHYLLINE BLOOD LEVEL; VOMITING;

EID: 0029766891     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09081689     Document Type: Article

References (16)

1. Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airway disease. Drugs 1991; 42: 895-912.
2. 2-agonist. Eur Respir Rev 1993; 3(14): 391-395.
3. Weinberger M. Pharmacology and therapeutic use of theophylline. J Allergy Clin Immunol 1984; 73: 525-540.
4. Fjellbirkerland L, Gulsvik A, Palmer JBD. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained release theophylline in patients with reversible airway disease. Respir Med 1994; 88: 599-607.
5. Muir JF, Bertin L, Georges D. Salmeterol versus slow-release theophylline combined with ketotifen in nocturnal asthma: a multicentre trial. Eur Respir J 1992; 5: 1197-1200.
6. Quanjer PhH, Yammelin GI, Cotes JE, Pedersen OF, Peslin R, Yemault J-C. Lung volumes and forced ventilatory flows. Report Working Party "Standardization of Lung Function Tests", European Coal and Steel Community. Eur Respir J 1993; 6 (Suppl. 16): 5-40.
7. NHLBI. International consensus report on diagnosis and treatment of asthma. Eur Respir J 1992; 5: 601-641.
8. NHBLI. Guidelines for the diagnosis and management of asthma. J Allergy Clin Immunol 1991; 88: 425-533.
9. Hargreave FE, Dolovich J, Newhouse MT. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol 1990; 85: 1098-1111.
10. Laursen LC, Taudorf E, Grosspelius Y, Gymose E, Weeke B. Long-term oral therapy of asthma with terbutaline and theophylline, alone and combined. Eur J Respir Dis 1985; 66: 82-90.
11. Pierson WE, La Force CF, Bell TD, MacCosbe PE, Sykes RS, Tinkelman D. Long-term, double-blind comparison of controlled-release albuterol versus sustained-release theophylline in adolescents and adults with asthma. J Allergy Clin Immunol 1990; 85: 618-626.
12. Joad JP, Ahrens RC, Lindgren SD, Weinberger MM. Relative efficacy of maintenance therapy with theophylline, inhaled albuterol, and the combination for chronic asthma. J Allergy Clin Immunol 1987; 79: 78-85.
13. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062-1067.
14. Addis GJ, Johnston IDA. Theophylline in the management of airway obstruction. BMJ 1990; 300: 928-931.
15. Whiting B, Kelman AW, Struthers AD. Prediction of response to theophylline in chronic bronchitis. Br J Clin Pharmacol 1984; 17: 1-8.
16. Fairshter RD, Busse WW. Theophylline: how much is enough? J Allergy Clin Immunol 1986; 77: 646-648.